Collectively, these results strongly suggest that DNJ is effective in increasing oligomer levels of OPA1, rescuing mitochondrial function in HCM iPSC-CMs, and presents the potential for extended and broader clinical use of DNJ in other mitochondrial disease models. This evidence concerns the gene OPA1 and inborn mitochondrial metabolism disorder.